Agilent Announces Target Enrichment Manufacturing Facility in China
Agilent Technologies (NYSE: A) has established in-country manufacturing for its SureSelect portfolio at its Hangzhou, China facility. This move aims to enhance delivery turnaround times for next-generation sequencing assays, allowing faster development and optimization of custom panels. The new manufacturing site will maintain the same high-quality standards as U.S. counterparts, enabling quicker customer access to assay technology. Agilent's investment reflects its commitment to growth opportunities in the China market and reinforces its genomics capabilities.
- Establishment of local manufacturing in China for SureSelect products will reduce delivery turnaround time.
- Maintaining ISO 13485:2016 standards ensures high-quality production.
- Enhanced ability to develop and optimize custom panels quickly for clients.
- None.
Agilent Technologies Inc. (NYSE: A) today announced that is has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China.
Agilent is a leading provider of next-generation sequencing assays, and customers often develop custom panels for their routine applications. Therefore, delivery turnaround time is an essential aspect of how Agilent uniquely serves its customers, enabling them to validate and implement their assays quickly and efficiently.
Expanding manufacturing capabilities for SureSelect assays in China, at the same high-quality standard (ISO 13485:2016) as Agilent’s U.S.-based manufacturing sites, will significantly reduce the time from initial design to customer delivery. In addition, China-based manufacturing will provide faster development and iteration on custom panel optimization and more rapid supply for routine sequencing applications.
“Agilent’s investment in developing and expanding our manufacturing capabilities for SureSelect products represents an example of our commitment to continuous improvement and the growth opportunities we foresee in the China market," said Kevin Meldrum, vice president and general manager for Agilent's Genomics Division. “This investment in China ensures that our customers there will have ready access to our assay technology as a local partner that can meet their unique needs.”
As a company, Agilent has a long track record of investing in the China market. This announcement extends and reinforces the company’s commitment to China, genomics and our NGS portfolio by embracing and adapting to local market needs.
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005647/en/
FAQ
What recent announcement did Agilent Technologies make regarding its manufacturing capabilities?
How will the new facility in China impact Agilent's delivery times?
What quality standards will the new Agilent manufacturing site in China uphold?
Why is Agilent expanding its manufacturing capabilities in China?
What are the benefits of the new Agilent facility for custom panel development?
